Design. Execute. Accelerate.
Senior clinical development judgment, connected to controlled execution
Manolo Beelke & Partners helps sponsors and investors make better clinical-development decisions before expensive assumptions become locked into protocols, budgets, vendor plans or financing narratives. We combine medical, regulatory, payer, commercial and operational logic into one evidence architecture, then connect it to execution through Verum and NECTAR.
Seven entry points
Choose the mandate
Start with the decision or execution problem that is putting value at risk.
Senior ownership
Fractional CMO & Medical Leadership
Accountable CMO-level judgment for clinical strategy, board alignment and execution governance.
Design
Clinical Development Strategy & Pivotal Trial Design
Evidence architecture, endpoint logic, estimands, feasibility and pivotal readiness.
Recovery
Trial Rescue & Execution Governance
Restore signal integrity, feasibility realism and execution control before decision value is lost.
Evidence
Regulatory, HTA & Evidence Strategy
Align approval, payer relevance and evidence generation before requirements diverge.
Capital
Investor Due Diligence & Asset Development
Clinical risk maps, value gates and fundable development plans that withstand technical diligence.
Scientific authority
Medical Affairs & Market Access
Connect scientific narrative, evidence strategy, external insight and adoption credibility.
Execution
Operational Execution with Excellence
Governed global execution through Verum and qualified local reach through NECTAR.
From strategy to controlled execution
One clinical architecture. One governance system.
Strong clinical development does not fail only in strategy. It fails when strategy is not translated into executable country, site, vendor, quality and evidence decisions. MB&P defines the clinical architecture. Verum provides the accountable execution spine. NECTAR adds qualified local CROs, specialist vendors, healthcare providers and clinical sites where regional depth improves regulatory fluency, patient access, recruitment realism and operational speed.
01
MB&P
Senior clinical architecture across medical, regulatory, payer, commercial and operational decisions.
03
NECTAR
Qualified regional CROs, specialist vendors, healthcare providers and sites under one governance logic.
Representative execution outcomes
Controlled execution, measured where it matters
Representative outcomes from selected programs and partner-network execution models. Results depend on indication, protocol complexity, geography and sponsor readiness.
+42%
faster FPI
Start-up acceleration through governed hub-and-spoke execution.
-28%
lower screen-fail rate
Better fit between protocol assumptions, site reality and patient selection.
5
continents
Coordinated multi-region execution under one governance logic.
Capital. Science.
From molecule to investable asset
Clinical value is not created by a promising mechanism alone. It is created when the program reaches decision-grade milestones with evidence that regulators, payers, partners and investors can trust.
- Clear gates: endpoints, assumptions and decision trees synchronized with financing rounds.
- Diligence-ready: protocol logic, risk register, quality evidence and governance artifacts built from the start.
- Interim readouts: timing, statistics and data packages designed for investment committees, not only internal updates.
Strategy. Execution. Evidence.
Guiding sponsors through every clinical phase
From indication fit to Phase I-IV execution, we combine protocol craftsmanship with NECTAR-enabled delivery so programs remain interpretable at database lock and credible after the readout.
- Design that works: population, endpoints, estimands and comparator logic built for regulatory and payer scrutiny.
- Execution engine: country and site strategy, rater quality control, vendor governance, RBQM and timeline control.
- Recruitment reality: feasibility grounded in patient flow, site capacity, competition and protocol burden.
Results
What clients and colleagues say
The recurring pattern is senior medical judgment, operational realism and the ability to turn complexity into decisions.
His contribution, commitment and professionalism have been truly outstanding.
Dr. Angelico Carta, MD
President & Co-Founder, Worldwide Clinical Trials
He quickly earned the reputation of the go-to expert.
Ram Yeleswarapu
Co-founder and past President/CEO, Navitas Life Sciences
A highly respected medical expert with deep, practical operational insight. Extremely rare and valuable.
Steve Galen, PhD
Former Global Head, Clinical Division, Navitas Life Sciences
Excellent European medical direction and guidance. I would work with him again in a heartbeat.
Arianna Pesci
Clinical Team Manager, Strategic Solutions
He stands out thanks to his originality of thinking and outstanding ability to give scientific contributions.
Mauro Manconi, MD, PhD
Head, Sleep & Epilepsy Center, Neurocenter of Southern Switzerland
Science. System. Soul.
We develop people who deliver outcomes
Clinical development succeeds when teams make clean decisions under pressure. Three academies build the judgment, communication and operating habits that turn strategy into execution.
Leadership
Areté Leadership Academy
Decision quality, communication, resilience and team performance when ambiguity is high.
Clinical development
Clinical Development Excellence Academy
Integrated development judgment from development thesis through evidence, execution and database lock.
Medical Affairs
Medical Affairs Strategy Academy
Scientific authority, evidence generation, Field Medical intelligence and insight-to-action governance.
A decision-grade next step
What decision cannot afford to be wrong?
Bring one live decision, the next hard milestone and the time available. Start with a focused 20-minute diagnostic.
